Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today released a letter to shareholders from its Chief Executive Officer Dr. David Young. In the letter, Dr. Young shared 2021 accomplishments and the company’s planned path forward. “We believe 2022 will be a transformative year for Processa as our multi-asset pipeline continues to mature and we achieve important clinical milestones. Our pipeline is different from that of other biotech companies because each of our drugs have a ‘de-risked’ development path forward,” Dr. Young writes, describing the company’s unique approach. “Processa is a ‘drug development company’ not a drug discovery company. Our pipeline of drugs does not include a new drug class or new drug target like many discovery companies. Our efforts and energies are directed toward advancing each program as efficiently as possible to the next development stage while obtaining information that will assist us in ultimately obtaining marketing authorization from regulatory agencies. Our past experiences in previous companies have been well rewarded when we have followed our Regulatory Science approach to focus on development activities rather than the associated risks of drug discovery.”
To view the full press release, visit https://ibn.fm/dwYFK
About Processa Pharmaceuticals Inc.
The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.